z-logo
open-access-imgOpen Access
Role of inhibitor of yes‐associated protein 1 in triple‐negative breast cancer with taxol‐based chemoresistance
Author(s) -
Li Ying,
Wang Shunan,
Wei Xi,
Zhang Sheng,
Song Zian,
Chen Xiao,
Zhang Jin
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13888
Subject(s) - verteporfin , triple negative breast cancer , cancer research , paclitaxel , gene knockdown , epithelial–mesenchymal transition , breast cancer , apoptosis , medicine , cancer , metastasis , biology , surgery , biochemistry , visual acuity , choroidal neovascularization
Triple‐negative breast cancer ( TNBC ) is highly clinically aggressive and taxol‐based chemoresistance remains a big TNBC therapeutic problem to be solved. Verteporfin, a small molecular yes‐associated protein 1 ( YAP 1) inhibitor, is little known as an antitumor drug for TNBC . Our data showed that YAP 1 expression was associated with early relapse in tissue samples of patients with TNBC taxol chemoresistance ( P  < .001). Verteporfin reduced migration and enhanced apoptosis or autophagy of a taxol‐resistant MDA ‐ MB ‐231 cell line in vitro. Knockdown of YAP 1 increased epithelial‐mesenchymal transition response in a taxol‐resistant TNBC cell line. In an in vivo experiment, we found that verteporfin was able to shrink tumor weight and volume and decreased Ki67 expression in a taxol‐resistant mouse model. Our results provide evidence that verteporfin could be a chemosensitizer for TNBC patients with taxol‐based treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here